13

Time Title Name Affilation
08:00~08:30 Registration  
08:30~08:40 Opening remarks  Eui-Cheol Shin KAI Immuno-Oncology Interest Group Leader
 Session I. Cell-based cancer immunotherapy  
Chair : Chang-Yuil Kang (Seoul National Univ.)
You-Me Kim (KAIST)
08:40~09:20 Engineering Next Generation CAR T cells to Overcome Resistance Crystal Mackall Stanford Univ.
09:20~10:00 Understanding resistance to develop novel effective CART immunotherapies Marco Ruella Univ. of Pennsylvania
10:00~10:20 Coffee break
10:20~10:50 Adoptive CAST, cancer antigen-specific T cell, therapy Byoung S. Kwon Eutilex
10:50~11:30 CAR T Immunotherapy – Opportunities and Challenges Stephan Grupp Children's Hospital of Philadelphia
11:30~12:00 Luncheon symposium CyTek Biosciences  
12:00~13:20 Lunch 
 Session II. Basic understanding of cancer immunotherapy
Chair : Eui-Cheol Shin (KAIST)
Hun Sik Kim (Univ. of Ulsan)
13:20~14:00 Defining T Cell Exhaustion: Implications for Immunotherapy Rafi Ahmed Emory Univ.
14:00~14:30 Differentiation and function of Tc17 cells in tumor Yeonseok Chung Seoul National Univ.
14:30~14:50 Characteristics of tumor-infiltrating CD28null CD8+ T cells and their reinvigoration Kyung Hwan Kim KAIST
14:50~15:10 Plasticity of ILCs by tumor cells in lung tumor microenvironment Jaemoon Koh Seoul National Univ.
15:10~15:50 The role of CD8+ suppressor cell in regulating immunotherapy efficacy Brian Gastman Cleveland Clinic
15:50~16:10 Coffee break
 Session III. Development and application of cancer immunotherapy
Chair : Joohyuk Sohn (Yonsei Univ.)
Tae Woo Kim (Korea Univ.)
16:10~16:40 Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves activity of cancer immunotherapy  Seung-Woo Lee  POSTECH 
16:40~17:20 Emerging therapeutic antibodies in immuno-oncology Jingwu Zang I-Mab
17:20~17:50 ABL503, bispecific antibody targeting PD-L1 and 4-1BB: Strategic way to develop a next generation immunotherapy Jaeho Jung ABL Bio
17:50~18:20 Hyleukin-7 as T cell deficiency correcting drug in cancer therapy Yun Jung Choi Genexine
18:20~18:30 Closing remarks